Skip to content
MARKETS / NASDAQ / SMTI
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

Sanara MedTech Inc. SMTI

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$103.1M
▲ 19.0% YoY
$-37.6M
$2.2M
In brief

What this company does

Sanara MedTech Inc. primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. As of December 31, 2025, it had a staff of 108 full-time employees. Following the disposal of its Tissue Health Plus platform, it now has a single reportable segment. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen that aids in the management of surgical wounds, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation. Its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus Advanced Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. It was incorporated in Texas on December 14, 2001.

Written from the business description in Sanara MedTech Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 March 2026. Every sentence was checked against that document before publication.

Growth
USD 103.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 103.1 · Net income -37.6
40M80M-20M201020122014201620182020202220242025
Compound annual growth
+31.0%
+45.9%
+40.8%
+37.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +45.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−36 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 7.1% · Net -36.4%
-200%-400%-600%201020122014201620182020202220242025
ROE
FY2025 · ROE -165.7%
-500%-1000%201020122014201620182020202220242025

Each USD of equity lost 166 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 2.2
0.8M1.6M-2.0M-4.0M201020122014201620182020202220242025

Total assetsUSD 72.9M
EquityUSD 5.9M
CashUSD 16.6M
Gross debtUSD 46.0M
Net debtUSD 29.4M
Current ratio1.80×

Net debt stands at 495% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0··−0.0−0.0−0.0
EBITDA $B0.00.0−0.0−0.0−0.0−0.0−0.0······−0.0−0.0−0.0
Income tax $B·0.0·−0.0·0.00.00.00.00.00.00.00.0···
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.0−0.0···
EPS, diluted $−4.36−1.14−0.52−1.00−1.08−0.76−1.320.000.00−0.01−0.02−0.03−0.05−0.03−0.23−0.19
Dividend / sh $················
Payout %················
ROE %−165.7−22.9−9.9−21.9−43.1−69.6−78.2−174.2·······−1190.7
Shares out B0.010.010.010.010.010.010.000.000.110.110.110.090.090.070.060.04

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 78 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 17 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image